CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for PaxMedica Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

PaxMedica Inc
303 South Broadway, Suite 125
Phone: (914) 987-2876p:914 987-2876 TARRYTOWN, NY  10591  United States Ticker: PXMDPXMD

Business Summary
PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to neurodegenerative disorders, such as Fragile X Tremor Ataxia Syndrome (FXTAS) and post-viral Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its lead program PAX-101 is an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders fragile X syndrome (FXS), FXTAS, ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202412/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer Howard J.Weisman 63 8/21/2023 3/1/2020
Chief Financial Officer, Chief Operating Officer Stephen D.Sheldon 43 8/21/2023 7/1/2022
Lead Independent Director Charles J.Casamento 78 8/21/2023 10/1/2022
Independent Director John F.Coelho 54 5/1/2022 5/1/2022
Independent Director KarenLaRochelle 56 7/1/2020 7/1/2020

General Information
Number of Employees: 6 (As of 12/31/2023)
Outstanding Shares: 10,879,170 (As of 9/20/2024)
Shareholders: 10
Stock Exchange: OTC
Federal Tax Id: 850870387
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024